Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZUSA: Faricimab in Non-Proliferative Diabetic Retinopathy
jRCT2071250009Phase 3Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of faricimab in diabetic retinopathy (NPDR) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Proportion of participants achieving >= 2-step improvement in ETDRS-DRSS at Week 48. Started May 2025; status: recruiting.
02
Drugs
faricimab
03
Conditions
diabetic retinopathy (NPDR)
Beyond the preview
Go deeper on jRCT2071250009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250009.